206 related articles for article (PubMed ID: 15314544)
1. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy.
Ribas A; Glaspy JA; Lee Y; Dissette VB; Seja E; Vu HT; Tchekmedyian NS; Oseguera D; Comin-Anduix B; Wargo JA; Amarnani SN; McBride WH; Economou JS; Butterfield LH
J Immunother; 2004; 27(5):354-67. PubMed ID: 15314544
[TBL] [Abstract][Full Text] [Related]
2. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma.
Butterfield LH; Ribas A; Dissette VB; Amarnani SN; Vu HT; Oseguera D; Wang HJ; Elashoff RM; McBride WH; Mukherji B; Cochran AJ; Glaspy JA; Economou JS
Clin Cancer Res; 2003 Mar; 9(3):998-1008. PubMed ID: 12631598
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100.
Panelli MC; Wunderlich J; Jeffries J; Wang E; Mixon A; Rosenberg SA; Marincola FM
J Immunother; 2000; 23(4):487-98. PubMed ID: 10916759
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
Butterfield LH; Comin-Anduix B; Vujanovic L; Lee Y; Dissette VB; Yang JQ; Vu HT; Seja E; Oseguera DK; Potter DM; Glaspy JA; Economou JS; Ribas A
J Immunother; 2008 Apr; 31(3):294-309. PubMed ID: 18317358
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma.
Ribas A; Comin-Anduix B; Chmielowski B; Jalil J; de la Rocha P; McCannel TA; Ochoa MT; Seja E; Villanueva A; Oseguera DK; Straatsma BR; Cochran AJ; Glaspy JA; Hui L; Marincola FM; Wang E; Economou JS; Gomez-Navarro J
Clin Cancer Res; 2009 Oct; 15(19):6267-76. PubMed ID: 19789309
[TBL] [Abstract][Full Text] [Related]
6. Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity.
Kalady MF; Onaitis MW; Emani S; Abdel-Wahab Z; Tyler DS; Pruitt SK
J Surg Res; 2004 Jan; 116(1):24-31. PubMed ID: 14732346
[TBL] [Abstract][Full Text] [Related]
7. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma.
Chodon T; Comin-Anduix B; Chmielowski B; Koya RC; Wu Z; Auerbach M; Ng C; Avramis E; Seja E; Villanueva A; McCannel TA; Ishiyama A; Czernin J; Radu CG; Wang X; Gjertson DW; Cochran AJ; Cornetta K; Wong DJ; Kaplan-Lefko P; Hamid O; Samlowski W; Cohen PA; Daniels GA; Mukherji B; Yang L; Zack JA; Kohn DB; Heath JR; Glaspy JA; Witte ON; Baltimore D; Economou JS; Ribas A
Clin Cancer Res; 2014 May; 20(9):2457-65. PubMed ID: 24634374
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial.
Oshita C; Takikawa M; Kume A; Miyata H; Ashizawa T; Iizuka A; Kiyohara Y; Yoshikawa S; Tanosaki R; Yamazaki N; Yamamoto A; Takesako K; Yamaguchi K; Akiyama Y
Oncol Rep; 2012 Oct; 28(4):1131-8. PubMed ID: 22895835
[TBL] [Abstract][Full Text] [Related]
9. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
Lesterhuis WJ; de Vries IJ; Schreibelt G; Lambeck AJ; Aarntzen EH; Jacobs JF; Scharenborg NM; van de Rakt MW; de Boer AJ; Croockewit S; van Rossum MM; Mus R; Oyen WJ; Boerman OC; Lucas S; Adema GJ; Punt CJ; Figdor CG
Clin Cancer Res; 2011 Sep; 17(17):5725-35. PubMed ID: 21771874
[TBL] [Abstract][Full Text] [Related]
10. CTLA4 blockade maximizes antitumor T-cell activation by dendritic cells presenting idiotype protein or opsonized anti-CD20 antibody-coated lymphoma cells.
Hsu FJ; Komarovskaya M
J Immunother; 2002; 25(6):455-68. PubMed ID: 12439343
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell gene therapy.
Onaitis M; Kalady MF; Pruitt S; Tyler DS
Surg Oncol Clin N Am; 2002 Jul; 11(3):645-60. PubMed ID: 12487060
[TBL] [Abstract][Full Text] [Related]
13. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
[TBL] [Abstract][Full Text] [Related]
14. Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay.
Pass HA; Schwarz SL; Wunderlich JR; Rosenberg SA
Cancer J Sci Am; 1998; 4(5):316-23. PubMed ID: 9815296
[TBL] [Abstract][Full Text] [Related]
15. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients.
Hodi FS; Mihm MC; Soiffer RJ; Haluska FG; Butler M; Seiden MV; Davis T; Henry-Spires R; MacRae S; Willman A; Padera R; Jaklitsch MT; Shankar S; Chen TC; Korman A; Allison JP; Dranoff G
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4712-7. PubMed ID: 12682289
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
Ribas A; Camacho LH; Lopez-Berestein G; Pavlov D; Bulanhagui CA; Millham R; Comin-Anduix B; Reuben JM; Seja E; Parker CA; Sharma A; Glaspy JA; Gomez-Navarro J
J Clin Oncol; 2005 Dec; 23(35):8968-77. PubMed ID: 16204013
[TBL] [Abstract][Full Text] [Related]
17. Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen.
Smithers M; O'Connell K; MacFadyen S; Chambers M; Greenwood K; Boyce A; Abdul-Jabbar I; Barker K; Grimmett K; Walpole E; Thomas R
Cancer Immunol Immunother; 2003 Jan; 52(1):41-52. PubMed ID: 12536239
[TBL] [Abstract][Full Text] [Related]
18. Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma.
Palucka AK; Dhodapkar MV; Paczesny S; Burkeholder S; Wittkowski KM; Steinman RM; Fay J; Banchereau J
J Immunother; 2003; 26(5):432-9. PubMed ID: 12973032
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells.
Mahdian R; Kokhaei P; Najar HM; Derkow K; Choudhury A; Mellstedt H
Med Oncol; 2006; 23(2):273-82. PubMed ID: 16720928
[TBL] [Abstract][Full Text] [Related]
20. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ
Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
